Home

Download

Statistics

Examples

Help

Contact

Fusion Protein:ARHGAP15-ZEB2

Fusion Gene and Fusion Protein Summary

Fusion gene summary

Fusion partner gene information	Fusion gene name: ARHGAP15-ZEB2
	FusionPDB ID: 5955
	FusionGDB2.0 ID: 5955
		Hgene	Tgene
	Gene symbol	ARHGAP15	ZEB2
	Gene ID	55843	9839
	Gene name	Rho GTPase activating protein 15	zinc finger E-box binding homeobox 2
	Synonyms	BM046	HSPC082\|SIP-1\|SIP1\|SMADIP1\|ZFHX1B
	Cytomap	2q22.2-q22.3	2q22.3
	Type of gene	protein-coding	protein-coding
	Description	rho GTPase-activating protein 15rho-type GTPase-activating protein 15	zinc finger E-box-binding homeobox 2SMAD interacting protein 1Smad-interacting protein 1zinc finger homeobox 1b
	Modification date	20200313	20200329
	UniProtAcc	Q53QZ3 Main function of 5'-partner protein: FUNCTION: GTPase activator for the Rho-type GTPases by converting them to an inactive GDP-bound state. Has activity toward RAC1. Overexpression results in an increase in actin stress fibers and cell contraction. {ECO:0000269\|PubMed:12650940}.	.
Ensembl transtripts involved in fusion gene	ENST ids	ENST00000295095, ENST00000409869, ENST00000473426,	ENST00000462355, ENST00000465070, ENST00000470879, ENST00000493689, ENST00000303660, ENST00000409487, ENST00000539609, ENST00000558170,
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)	* DoF score	15 X 13 X 5=975	5 X 5 X 3=75
	# samples	16	5
	** MAII score	log2(16/975*10)=-2.60733031374961 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0	log2(5/75*10)=-0.584962500721156 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0
Fusion gene context	PubMed: ARHGAP15 [Title/Abstract] AND ZEB2 [Title/Abstract] AND fusion [Title/Abstract]
Fusion neoantigen context	PubMed: ARHGAP15 [Title/Abstract] AND ZEB2 [Title/Abstract] AND neoantigen [Title/Abstract]
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)	ZEB2(145274845)-ARHGAP15(144460988), # samples:3 ARHGAP15(144314054)-ZEB2(145187593), # samples:1
Anticipated loss of major functional domain due to fusion event.	ARHGAP15-ZEB2 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. ARHGAP15-ZEB2 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. ARHGAP15-ZEB2 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. ARHGAP15-ZEB2 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.

* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez

Partner	Gene	GO ID	GO term	PubMed ID
Hgene	ARHGAP15	GO:0008360	regulation of cell shape	12650940
Tgene	ZEB2	GO:0000122	negative regulation of transcription by RNA polymerase II	12837246\|20516212

Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr2:145274845/chr2:144460988)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.

Retention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

Fusion gene breakpoints across ARHGAP15 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Fusion gene breakpoints across ZEB2 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Top

Fusion Amino Acid Sequences

Fusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	Seq length (transcript)	BP loci (transcript)	Predicted start (transcript)	Predicted stop (transcript)	Seq length (amino acids)
ENST00000295095	ARHGAP15	chr2	144314054	+	ENST00000558170	ZEB2	chr2	145187593	-	10112	1170	167	4741	1524
ENST00000295095	ARHGAP15	chr2	144314054	+	ENST00000409487	ZEB2	chr2	145187593	-	6192	1170	167	4741	1524
ENST00000295095	ARHGAP15	chr2	144314054	+	ENST00000303660	ZEB2	chr2	145187593	-	6179	1170	167	4741	1524
ENST00000295095	ARHGAP15	chr2	144314054	+	ENST00000539609	ZEB2	chr2	145187593	-	6104	1170	167	4669	1500

DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	No-coding score	Coding score
ENST00000295095	ENST00000558170	ARHGAP15	chr2	144314054	+	ZEB2	chr2	145187593	-	0.000166965	0.999833
ENST00000295095	ENST00000409487	ARHGAP15	chr2	144314054	+	ZEB2	chr2	145187593	-	0.000304298	0.9996958
ENST00000295095	ENST00000303660	ARHGAP15	chr2	144314054	+	ZEB2	chr2	145187593	-	0.000308134	0.99969184
ENST00000295095	ENST00000539609	ARHGAP15	chr2	144314054	+	ZEB2	chr2	145187593	-	0.000297175	0.99970275

Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for ARHGAP15-ZEB2

+/-13 AA sequence from the breakpoints of the fusion protein sequences.

Hgene	Hchr	Hbp	Tgene	Tchr	Tbp	Length(fusion protein)	BP in fusion protein	Peptide
ARHGAP15	chr2	144314054	ZEB2	chr2	145187593	1170	334	LATIQKLRFIVNQVVNYDNVVDTGSE

Top

Potential FusionNeoAntigen Information of ARHGAP15-ZEB2 in HLA I

Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.

ARHGAP15-ZEB2_144314054_145187593.msa

Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA I	FusionNeoAntigen peptide	Binding score	Immunogenic score	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	HLA-B27:04	LRFIVNQVV	0.9992	0.7557	6	15
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	HLA-B15:01	FIVNQVVNY	0.9985	0.8356	8	17
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	HLA-B15:25	FIVNQVVNY	0.9971	0.8222	8	17
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	HLA-B39:06	LRFIVNQVV	0.9917	0.8801	6	15
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	HLA-B15:02	FIVNQVVNY	0.9886	0.8508	8	17
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	HLA-A30:08	KLRFIVNQV	0.9843	0.7391	5	14
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	HLA-A02:13	KLRFIVNQV	0.9831	0.5515	5	14
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	HLA-B35:08	FIVNQVVNY	0.9813	0.7447	8	17
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	HLA-B35:01	FIVNQVVNY	0.9684	0.8574	8	17
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	HLA-A02:11	KLRFIVNQV	0.9363	0.6824	5	14
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	HLA-A02:04	KLRFIVNQV	0.9046	0.7134	5	14
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	HLA-A02:16	KLRFIVNQV	0.9033	0.5776	5	14
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	HLA-A02:20	KLRFIVNQV	0.7799	0.6526	5	14
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	HLA-B13:02	KLRFIVNQV	0.1894	0.6674	5	14
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	HLA-B27:04	LRFIVNQVVNY	0.9999	0.6484	6	17
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	HLA-B27:05	LRFIVNQVVNY	0.9999	0.8708	6	17
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	HLA-B27:14	LRFIVNQVV	0.9992	0.8933	6	15
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	HLA-B73:01	LRFIVNQVV	0.9927	0.8432	6	15
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	HLA-B15:21	FIVNQVVNY	0.9873	0.8389	8	17
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	HLA-B15:05	FIVNQVVNY	0.9828	0.7838	8	17
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	HLA-C07:05	LRFIVNQVV	0.9738	0.9667	6	15
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	HLA-B15:31	FIVNQVVNY	0.9658	0.7969	8	17
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	HLA-B39:12	LRFIVNQVV	0.9656	0.9229	6	15
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	HLA-B15:04	KLRFIVNQV	0.5379	0.9257	5	14
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	HLA-C12:04	FIVNQVVNY	0.5236	0.993	8	17
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	HLA-C15:04	FIVNQVVNY	0.503	0.776	8	17
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	HLA-C03:14	FIVNQVVNY	0.2209	0.9603	8	17
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	HLA-C12:16	LRFIVNQVV	0.0174	0.9776	6	15
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	HLA-B27:03	LRFIVNQVVNY	0.9987	0.8859	6	17
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	HLA-B27:06	LRFIVNQVV	0.9994	0.7491	6	15
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	HLA-B27:09	LRFIVNQVV	0.9993	0.9128	6	15
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	HLA-B27:08	LRFIVNQVV	0.999	0.8439	6	15
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	HLA-B15:27	FIVNQVVNY	0.9986	0.8188	8	17
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	HLA-B15:33	FIVNQVVNY	0.9985	0.8356	8	17
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	HLA-B15:125	FIVNQVVNY	0.9985	0.8356	8	17
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	HLA-B15:34	FIVNQVVNY	0.9985	0.8356	8	17
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	HLA-B15:135	FIVNQVVNY	0.9982	0.8148	8	17
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	HLA-B15:50	FIVNQVVNY	0.9979	0.8807	8	17
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	HLA-B15:11	FIVNQVVNY	0.9965	0.7909	8	17
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	HLA-B15:08	FIVNQVVNY	0.9964	0.7901	8	17
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	HLA-A02:03	KLRFIVNQV	0.9961	0.7473	5	14
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	HLA-B15:39	FIVNQVVNY	0.9957	0.6856	8	17
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	HLA-B35:43	FIVNQVVNY	0.9949	0.7892	8	17
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	HLA-B15:35	FIVNQVVNY	0.993	0.8041	8	17
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	HLA-B15:12	FIVNQVVNY	0.9922	0.8658	8	17
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	HLA-B35:11	FIVNQVVNY	0.9866	0.8327	8	17
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	HLA-B15:20	FIVNQVVNY	0.9862	0.8708	8	17
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	HLA-A30:01	KLRFIVNQV	0.9854	0.8957	5	14
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	HLA-B35:28	FIVNQVVNY	0.973	0.8665	8	17
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	HLA-B35:77	FIVNQVVNY	0.9684	0.8574	8	17
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	HLA-B35:23	FIVNQVVNY	0.9682	0.8088	8	17
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	HLA-B35:20	FIVNQVVNY	0.9579	0.8791	8	17
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	HLA-C03:02	FIVNQVVNY	0.9517	0.938	8	17
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	HLA-A25:01	FIVNQVVNY	0.9491	0.8059	8	17
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	HLA-C06:08	LRFIVNQVV	0.9443	0.996	6	15
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	HLA-C12:02	FIVNQVVNY	0.9263	0.9552	8	17
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	HLA-B35:17	FIVNQVVNY	0.8981	0.5749	8	17
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	HLA-B35:30	FIVNQVVNY	0.8981	0.5749	8	17
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	HLA-B35:24	FIVNQVVNY	0.7619	0.8598	8	17
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	HLA-C15:09	FIVNQVVNY	0.503	0.776	8	17
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	HLA-C06:17	LRFIVNQVV	0.1042	0.9972	6	15
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	HLA-C06:02	LRFIVNQVV	0.1042	0.9972	6	15
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	HLA-C02:02	FIVNQVVNY	0.0482	0.9591	8	17
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	HLA-C02:10	FIVNQVVNY	0.0482	0.9591	8	17
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	HLA-B27:10	LRFIVNQVVNY	0.9999	0.8027	6	17
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	HLA-B27:08	LRFIVNQVVNY	0.9999	0.6902	6	17

Top

Potential FusionNeoAntigen Information of ARHGAP15-ZEB2 in HLA II

ARHGAP15-ZEB2_144314054_145187593.msa

Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA II	FusionNeoAntigen peptide	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-0338	QKLRFIVNQVVNYDN	4	19
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-0338	KLRFIVNQVVNYDNV	5	20
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-0338	IQKLRFIVNQVVNYD	3	18
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-0340	QKLRFIVNQVVNYDN	4	19
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-0340	KLRFIVNQVVNYDNV	5	20
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-0478	IQKLRFIVNQVVNYD	3	18
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-0819	IQKLRFIVNQVVNYD	3	18
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-0819	QKLRFIVNQVVNYDN	4	19
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-0825	IQKLRFIVNQVVNYD	3	18
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-0825	QKLRFIVNQVVNYDN	4	19
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-0825	KLRFIVNQVVNYDNV	5	20
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-0834	IQKLRFIVNQVVNYD	3	18
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-0834	QKLRFIVNQVVNYDN	4	19
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1222	QKLRFIVNQVVNYDN	4	19
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1222	IQKLRFIVNQVVNYD	3	18
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1222	KLRFIVNQVVNYDNV	5	20
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1222	TIQKLRFIVNQVVNY	2	17
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1331	QKLRFIVNQVVNYDN	4	19
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1331	IQKLRFIVNQVVNYD	3	18
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1367	QKLRFIVNQVVNYDN	4	19
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1367	IQKLRFIVNQVVNYD	3	18
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1385	KLRFIVNQVVNYDNV	5	20
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1385	QKLRFIVNQVVNYDN	4	19
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1386	KLRFIVNQVVNYDNV	5	20
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1386	QKLRFIVNQVVNYDN	4	19
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1396	QKLRFIVNQVVNYDN	4	19
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1396	KLRFIVNQVVNYDNV	5	20
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1402	KLRFIVNQVVNYDNV	5	20
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1402	QKLRFIVNQVVNYDN	4	19
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1410	IQKLRFIVNQVVNYD	3	18
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1410	QKLRFIVNQVVNYDN	4	19
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1410	TIQKLRFIVNQVVNY	2	17
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1419	QKLRFIVNQVVNYDN	4	19
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1419	KLRFIVNQVVNYDNV	5	20
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1424	QKLRFIVNQVVNYDN	4	19
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1424	KLRFIVNQVVNYDNV	5	20
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1424	IQKLRFIVNQVVNYD	3	18
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1439	IQKLRFIVNQVVNYD	3	18
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1441	KLRFIVNQVVNYDNV	5	20
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1441	QKLRFIVNQVVNYDN	4	19
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1446	QKLRFIVNQVVNYDN	4	19
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1446	KLRFIVNQVVNYDNV	5	20
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1446	IQKLRFIVNQVVNYD	3	18
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1447	KLRFIVNQVVNYDNV	5	20
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1447	QKLRFIVNQVVNYDN	4	19
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1447	IQKLRFIVNQVVNYD	3	18
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1447	LRFIVNQVVNYDNVV	6	21
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1448	QKLRFIVNQVVNYDN	4	19
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1448	KLRFIVNQVVNYDNV	5	20
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1448	IQKLRFIVNQVVNYD	3	18
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1449	QKLRFIVNQVVNYDN	4	19
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1449	KLRFIVNQVVNYDNV	5	20
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1449	IQKLRFIVNQVVNYD	3	18
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1451	QKLRFIVNQVVNYDN	4	19
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1451	KLRFIVNQVVNYDNV	5	20
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1457	VNQVVNYDNVVDTGS	10	25
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1489	QKLRFIVNQVVNYDN	4	19
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1489	KLRFIVNQVVNYDNV	5	20
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1489	IQKLRFIVNQVVNYD	3	18
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1493	QKLRFIVNQVVNYDN	4	19
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1493	KLRFIVNQVVNYDNV	5	20
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1493	IQKLRFIVNQVVNYD	3	18
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1494	KLRFIVNQVVNYDNV	5	20
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1494	QKLRFIVNQVVNYDN	4	19
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1498	QKLRFIVNQVVNYDN	4	19
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1498	KLRFIVNQVVNYDNV	5	20
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1498	IQKLRFIVNQVVNYD	3	18
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1501	IQKLRFIVNQVVNYD	3	18
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1502	IQKLRFIVNQVVNYD	3	18
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1504	IQKLRFIVNQVVNYD	3	18
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1505	IQKLRFIVNQVVNYD	3	18
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1506	IQKLRFIVNQVVNYD	3	18
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1507	IQKLRFIVNQVVNYD	3	18
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1507	VNQVVNYDNVVDTGS	10	25
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1508	IQKLRFIVNQVVNYD	3	18
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1509	IQKLRFIVNQVVNYD	3	18
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1510	IQKLRFIVNQVVNYD	3	18
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1511	IQKLRFIVNQVVNYD	3	18
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1512	VNQVVNYDNVVDTGS	10	25
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1512	IVNQVVNYDNVVDTG	9	24
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1512	NQVVNYDNVVDTGSE	11	26
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1512	FIVNQVVNYDNVVDT	8	23
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1512	IQKLRFIVNQVVNYD	3	18
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1513	IQKLRFIVNQVVNYD	3	18
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1514	IQKLRFIVNQVVNYD	3	18
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1516	IQKLRFIVNQVVNYD	3	18
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1518	IQKLRFIVNQVVNYD	3	18
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1519	IQKLRFIVNQVVNYD	3	18
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1520	IQKLRFIVNQVVNYD	3	18
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1521	IQKLRFIVNQVVNYD	3	18
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1521	TIQKLRFIVNQVVNY	2	17
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1521	QKLRFIVNQVVNYDN	4	19
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1522	IQKLRFIVNQVVNYD	3	18
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1524	IQKLRFIVNQVVNYD	3	18
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1525	IQKLRFIVNQVVNYD	3	18
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1526	IQKLRFIVNQVVNYD	3	18
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1527	IQKLRFIVNQVVNYD	3	18
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1528	IQKLRFIVNQVVNYD	3	18
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1529	IQKLRFIVNQVVNYD	3	18
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1530	IQKLRFIVNQVVNYD	3	18
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1531	IQKLRFIVNQVVNYD	3	18
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1532	IQKLRFIVNQVVNYD	3	18
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1533	IQKLRFIVNQVVNYD	3	18
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1534	IQKLRFIVNQVVNYD	3	18
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1535	IQKLRFIVNQVVNYD	3	18
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1536	IQKLRFIVNQVVNYD	3	18
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1537	IQKLRFIVNQVVNYD	3	18
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1537	TIQKLRFIVNQVVNY	2	17
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1538	IQKLRFIVNQVVNYD	3	18
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1539	IQKLRFIVNQVVNYD	3	18
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1540	IQKLRFIVNQVVNYD	3	18
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1541	IQKLRFIVNQVVNYD	3	18
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1542	IQKLRFIVNQVVNYD	3	18
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1543	IQKLRFIVNQVVNYD	3	18
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1544	IQKLRFIVNQVVNYD	3	18
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1545	IQKLRFIVNQVVNYD	3	18
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1546	IQKLRFIVNQVVNYD	3	18
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1547	IQKLRFIVNQVVNYD	3	18
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1548	IQKLRFIVNQVVNYD	3	18
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1548	VNQVVNYDNVVDTGS	10	25
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1549	IQKLRFIVNQVVNYD	3	18
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1601	IQKLRFIVNQVVNYD	3	18
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1602	IQKLRFIVNQVVNYD	3	18
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1603	IQKLRFIVNQVVNYD	3	18
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1604	IQKLRFIVNQVVNYD	3	18
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1605	IQKLRFIVNQVVNYD	3	18
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1607	IQKLRFIVNQVVNYD	3	18
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1608	IQKLRFIVNQVVNYD	3	18
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1609	IQKLRFIVNQVVNYD	3	18
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1610	IQKLRFIVNQVVNYD	3	18
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1611	IQKLRFIVNQVVNYD	3	18
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1612	IQKLRFIVNQVVNYD	3	18
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1614	IQKLRFIVNQVVNYD	3	18
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1615	IQKLRFIVNQVVNYD	3	18
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1615	QKLRFIVNQVVNYDN	4	19
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1615	TIQKLRFIVNQVVNY	2	17
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB1-1616	IQKLRFIVNQVVNYD	3	18
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB3-0109	QKLRFIVNQVVNYDN	4	19
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB3-0109	KLRFIVNQVVNYDNV	5	20
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB3-0114	QKLRFIVNQVVNYDN	4	19
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB3-0114	KLRFIVNQVVNYDNV	5	20
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB3-0202	KLRFIVNQVVNYDNV	5	20
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB3-0202	QKLRFIVNQVVNYDN	4	19
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB3-0205	KLRFIVNQVVNYDNV	5	20
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB3-0205	QKLRFIVNQVVNYDN	4	19
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB3-0205	IQKLRFIVNQVVNYD	3	18
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB3-0209	QKLRFIVNQVVNYDN	4	19
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB3-0209	KLRFIVNQVVNYDNV	5	20
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB3-0209	IQKLRFIVNQVVNYD	3	18
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB3-0210	KLRFIVNQVVNYDNV	5	20
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB3-0210	QKLRFIVNQVVNYDN	4	19
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB3-0211	KLRFIVNQVVNYDNV	5	20
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB3-0211	QKLRFIVNQVVNYDN	4	19
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB3-0211	IQKLRFIVNQVVNYD	3	18
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB3-0212	KLRFIVNQVVNYDNV	5	20
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB3-0212	QKLRFIVNQVVNYDN	4	19
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB3-0213	KLRFIVNQVVNYDNV	5	20
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB3-0213	QKLRFIVNQVVNYDN	4	19
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB3-0214	KLRFIVNQVVNYDNV	5	20
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB3-0214	QKLRFIVNQVVNYDN	4	19
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB3-0215	QKLRFIVNQVVNYDN	4	19
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB3-0215	KLRFIVNQVVNYDNV	5	20
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB3-0216	QKLRFIVNQVVNYDN	4	19
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB3-0216	KLRFIVNQVVNYDNV	5	20
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB3-0216	IQKLRFIVNQVVNYD	3	18
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB3-0217	QKLRFIVNQVVNYDN	4	19
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB3-0217	KLRFIVNQVVNYDNV	5	20
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB3-0218	KLRFIVNQVVNYDNV	5	20
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB3-0218	QKLRFIVNQVVNYDN	4	19
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB3-0219	QKLRFIVNQVVNYDN	4	19
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB3-0219	KLRFIVNQVVNYDNV	5	20
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB3-0219	IQKLRFIVNQVVNYD	3	18
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB3-0220	KLRFIVNQVVNYDNV	5	20
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB3-0220	QKLRFIVNQVVNYDN	4	19
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB3-0221	QKLRFIVNQVVNYDN	4	19
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB3-0221	KLRFIVNQVVNYDNV	5	20
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB3-0221	IQKLRFIVNQVVNYD	3	18
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB3-0222	QKLRFIVNQVVNYDN	4	19
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB3-0222	KLRFIVNQVVNYDNV	5	20
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB3-0222	IQKLRFIVNQVVNYD	3	18
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB3-0223	KLRFIVNQVVNYDNV	5	20
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB3-0223	QKLRFIVNQVVNYDN	4	19
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB3-0225	KLRFIVNQVVNYDNV	5	20
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB3-0225	QKLRFIVNQVVNYDN	4	19
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB3-0303	QKLRFIVNQVVNYDN	4	19
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB3-0303	KLRFIVNQVVNYDNV	5	20
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	1170	DRB3-0303	IQKLRFIVNQVVNYD	3	18

Top

Fusion breakpoint peptide structures of ARHGAP15-ZEB2

3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.

File name	BPseq	Hgene	Tgene	Hchr	Hbp	Tchr	Tbp	AAlen
5516	LRFIVNQVVNYDNV	ARHGAP15	ZEB2	chr2	144314054	chr2	145187593	1170

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of ARHGAP15-ZEB2

Virtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.

HLA allele	PDB ID	File name	BPseq	Docking score	Glide score
HLA-B14:02	3BVN	5516	LRFIVNQVVNYDNV	-7.9962	-8.1096
HLA-B14:02	3BVN	5516	LRFIVNQVVNYDNV	-5.70842	-6.74372
HLA-B52:01	3W39	5516	LRFIVNQVVNYDNV	-6.83737	-6.95077
HLA-B52:01	3W39	5516	LRFIVNQVVNYDNV	-4.4836	-5.5189
HLA-A11:01	4UQ2	5516	LRFIVNQVVNYDNV	-10.0067	-10.1201
HLA-A11:01	4UQ2	5516	LRFIVNQVVNYDNV	-9.03915	-10.0745
HLA-A24:02	5HGA	5516	LRFIVNQVVNYDNV	-6.56204	-6.67544
HLA-A24:02	5HGA	5516	LRFIVNQVVNYDNV	-5.42271	-6.45801
HLA-B44:05	3DX8	5516	LRFIVNQVVNYDNV	-7.85648	-8.89178
HLA-B44:05	3DX8	5516	LRFIVNQVVNYDNV	-5.3978	-5.5112
HLA-A02:01	6TDR	5516	LRFIVNQVVNYDNV	-3.37154	-4.40684

Top

Vaccine Design for the FusionNeoAntigens of ARHGAP15-ZEB2

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide sequence	FusionNeoAntigen RNA sequence
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	5	14	KLRFIVNQV	AGTTAAGATTTATTGTCAACCAAGTGG
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	6	15	LRFIVNQVV	TAAGATTTATTGTCAACCAAGTGGTGA
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	6	17	LRFIVNQVVNY	TAAGATTTATTGTCAACCAAGTGGTGAACTATG
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	8	17	FIVNQVVNY	TTATTGTCAACCAAGTGGTGAACTATG

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide	FusionNEoAntigen RNA sequence
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	10	25	VNQVVNYDNVVDTGS	TCAACCAAGTGGTGAACTATGACAATGTAGTGGACACAGGTTCTG
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	11	26	NQVVNYDNVVDTGSE	ACCAAGTGGTGAACTATGACAATGTAGTGGACACAGGTTCTGAAA
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	2	17	TIQKLRFIVNQVVNY	CAATACAGAAGTTAAGATTTATTGTCAACCAAGTGGTGAACTATG
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	3	18	IQKLRFIVNQVVNYD	TACAGAAGTTAAGATTTATTGTCAACCAAGTGGTGAACTATGACA
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	4	19	QKLRFIVNQVVNYDN	AGAAGTTAAGATTTATTGTCAACCAAGTGGTGAACTATGACAATG
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	5	20	KLRFIVNQVVNYDNV	AGTTAAGATTTATTGTCAACCAAGTGGTGAACTATGACAATGTAG
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	6	21	LRFIVNQVVNYDNVV	TAAGATTTATTGTCAACCAAGTGGTGAACTATGACAATGTAGTGG
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	8	23	FIVNQVVNYDNVVDT	TTATTGTCAACCAAGTGGTGAACTATGACAATGTAGTGGACACAG
ARHGAP15-ZEB2	chr2	144314054	chr2	145187593	9	24	IVNQVVNYDNVVDTG	TTGTCAACCAAGTGGTGAACTATGACAATGTAGTGGACACAGGTT

Top

Information of the samples that have these potential fusion neoantigens of ARHGAP15-ZEB2

These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.

Cancer type	Fusion gene	Hchr	Hbp	Henst	Tchr	Tbp	Tenst	Sample
STAD	ARHGAP15-ZEB2	chr2	144314054	ENST00000295095	chr2	145187593	ENST00000303660	TCGA-BR-A4J9-01A

Top

Potential target of CAR-T therapy development for ARHGAP15-ZEB2

Predicted 3D structure. We used RoseTTAFold.

Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features

* Minus value of BPloci means that the break point is located before the CDS.

- In-frame and retained 'Transmembrane'.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Protein feature

Protein feature note

Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.

Hgene

Hchr

Hbp

Henst

Tgene

Tchr

Tbp

Tenst

DeepLoc result

Top

Related Drugs to ARHGAP15-ZEB2

Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Drug

Source

PMID

Top

Related Diseases to ARHGAP15-ZEB2

Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Disease

Source

PMID

Diseases associated with fusion partners.
(DisGeNet 4.0)

Partner

Gene

Disease ID

Disease name

# pubmeds

Source

	Fusion Gene and Fusion Protein Summary
	Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)
	Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)
	Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)
	Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)
	Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)
	Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)
	Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)
	Potential target of CAR-T therapy development
	Information on the samples that have these potential fusion neoantigens
	Fusion Protein Targeting Drugs - (Manual Curation)
	Fusion Protein Related diseases - (Manual Curation)